Investor Presentation

Date: 28th July 2026 The Manager Listing Compliance Department National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400051, India Symbol: SAKAR Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Presentation on the Un-Audited Financial Results. Please find attached the presentation on the Un-Audited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026. This is submitted for your information and records. Thanking You, Yours faithfully, FOR, SAKAR HEALTHCARE LIMITED BHARAT SONI COMPANY SECRETARY AND COMPLIANCE OFFICER Encl: As above SAKAR HEALTHCARE LIMITED Investor Presentation | Q1FY27 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sakar Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. Financial Performance Q1FY27 Operational Highlights • The oncology business continued to gain scale through an expanding product portfolio, wider market access and increasing export opportunities, positioning the company for stronger momentum in FY27 • Executed more than 65 oncology product contracts, with over 50 commercial discussions currently underway. • Shared 261 dossiers globally, of which 178 have been submitted and 16 have received Marketing Authorisations. • Shared dossiers for 21 of the 32 developed oncology products, securing 16 dossier approvals. • Completed 26 EU Marketing Authorisation filings, including 15 owned filings. Further 6 MAs procured through partners in Bulgaria and Bosnia, rest has been filed that includes Czech Republic, Croatia and Poland. • Submitted 33 site variations covering 18 cytotoxic molecules across the EU and the UK, of which seven have been approved. • Developed 21 APIs in-house, including, 16 APIs with Written Confirmation, 8 Commercialised products, 2 API’s with CEP approval, 5 CEP applications currently in process. • 33 Technology transfer projects for oncology products are underway with Accord-Intas, Torrent in the UK and Germany, Emcure, Glenmark, and Zydus. Of these projects, 7 have received site variation approvals —two in the UK and five in the EU. • The Zydus Lifesciences partnership for GCC and other emerging markets marked Sakar’s 40th global anti-cancer product agreement. • Sakar is transitioning towards an integrated, regulatory-driven business model, supported by greater value-chain integration and stronger operational capabilities, thereby improving supply-chain control, margin visibility, and scalability. • A growing pipeline of regulatory approvals positions the company for its next phase of growth, enabling it to expand market share and deliver sustained earnings momentum. Q1 FY27 – Consolidated Financial Highlights INR in Lakhs Revenue EBITDA PAT +38.37% +67.24% +120.17% 7,297 2,125 1,028 5,274 1,271 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1 FY27 Financial Highlights • Revenue from operations for Q1FY27 stood at ₹ 7,297 lakhs, reflecting 38% YoY growth. Performance was supported by new market authorizations with oncology products and strong demand across countries, alongside continued execution across key initiatives • EBITDA increased to ₹ 2,125 lakhs, up 67% YoY; EBITDA margins stood at 29% • Company delivered a strong improvement in profitability, with PAT at 1,028 Lakhs margin at 14% reflecting 120% YoY growth, reflecting operating leverage, improved efficiencies, and disciplined cost management Q1 FY27 – Consolidated Profit & Loss Statement Particulars (INR in Lakhs)​ Q1 FY27 Q1 FY26 Y-o-Y Q4 FY26 Q-o-Q FY26 Revenue from Operations 7,297.25 5,273.62 38% 7,109.70 3% 25,173.60 COGS​ 3,458.22 2,895.24 2,838.09 12,327.67 Gross Profit 3,839.03 2,378.38 61% 4,271.61 -10% 12,845.93 Gross Profit Margin (%) 53% 45% 60% 51% Employee Expenses ​ 1,145.51 754.96 1293.80 3,871.69 Other Expenses ​ 568.63 352.84 354.24 2,085.42 EBITDA 2,124.89 1,270.58 67% 2,623.57 -19% 6,888.82 EBITDA Margin (%) 29% 24% 37% 27% Other Income​ 154.39 39.39 17.12 228.74 Depreciation ​ 654.24 557.23 593.57 2,356.45 Finance Cost ​ 166.97 214.26 241.12 785.59 Profit before Tax 1,458.07 538.48 171% 1,806.00 -19% 3,975.52 Profit before Tax(%) 20% 10% 25% 16% Tax ​ 429.58 71.35 703.57 927.06 Profit After Tax 1,028.49 467.13 120% 1,102.43 -7% 3,048.46 PAT Margin (%) 14% 9% 16% 12% Basic EPS (As per Profit after Tax)​ 4.62 2.11 4.96 13.70 Company Overview From Vision to Value: Sakar Healthcare at a Glance • Founded by Mr. Sanjay Shah, Sakar Healthcare has evolved from a contract manufacturer into an API-integrated pharmaceutical organization with a strong presence across oral solids, injectables, and oncology formulations. • Over two decades, the company has built a reputation for credibility, compliance, and precision, supported by world-class WHO and EU-GMP certified facilities in Gujarat and a global network of partnerships across regulated markets. • The establishment of a state-of-the-art oncology facility at Bavla, equipped with integrated API and FDF capabilities, marks a defining milestone in Sakar’s transformation. This expansion elevates the company from a reliable formulation partner to a vertically integrated player in the global oncology space — combining scientific innovation, scalable manufacturing, and sustainable operations. • As it enters its next phase of growth, Sakar Healthcare stands positioned for onco-led value creation, leveraging its legacy of quality and research excellence to deliver specialized, high-compliance healthcare solutions worldw [Showing first 8,000 characters — download PDF for full document]